» Articles » PMID: 23136116

Mycobacterium Tuberculosis Region of Difference (RD) 2 Antigen Rv1985c and RD11 Antigen Rv3425 Have the Promising Potential to Distinguish Patients with Active Tuberculosis from M. Bovis BCG-vaccinated Individuals

Overview
Date 2012 Nov 9
PMID 23136116
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Antigens encoded in the region of difference (RD) of Mycobacterium tuberculosis constitute a potential source of specific immunodiagnostic antigens for distinguishing tuberculosis (TB) infection from BCG vaccination. We evaluated the diagnostic potential of specific T-cell epitopes selected from two immunodominant antigens, Rv1985c and Rv3425, from RD2 and RD11, respectively, on the basis of epitope mapping, in TB patients and BCG-vaccinated healthy individuals. Using a whole-blood gamma interferon release assay, a wide array of epitopes was recognized on both Rv1985c and Rv3425 in TB patients. Those epitopes that could specifically discriminate TB infection from BCG vaccination were carefully selected, and the most promising peptide pools from Rv1985c showed a sensitivity of 53.9% and a specificity of 95.5%. When the novel specific peptides from Rv1985c joined the diagnostic antigens in the QuantiFERON-TB Gold In-Tube (QFT-IT) assay, the sensitivity was increased from 86.4% to 96.2%, with no drop in specificity. These results indicate that the peptide pools selected from Rv1985c and Rv3425 have the potential to diagnose TB infection by a method that may be routinely used in clinical laboratories.

Citing Articles

The Diagnostic Value of Interleukin-2 and Interferon-γ Induced by Fusion Protein (ESAT-6/CFP-10/Rv1985c) for Active Mycobacterium tuberculosis Infection.

Zhao Z, Li R, Zhao X, Wang Y, Lin M, Wei Q J Clin Lab Anal. 2025; 39(5):e70010.

PMID: 40019050 PMC: 11904813. DOI: 10.1002/jcla.70010.


Construction of novel multi-epitope-based diagnostic biomarker HP16118P and its application in the differential diagnosis of Mycobacterium tuberculosis latent infection.

Wang J, Jiang F, Cheng P, Ye Z, Li L, Yang L Mol Biomed. 2024; 5(1):15.

PMID: 38679629 PMC: 11056354. DOI: 10.1186/s43556-024-00177-z.


Evaluation of immunodominant peptides of in vivo expressed mycobacterial antigens in an ELISA-based diagnostic assay for pulmonary tuberculosis.

Sharma S, Suri D, Aggarwal A, Yadav R, Sethi S, Laal S Braz J Microbiol. 2023; 54(3):1751-1759.

PMID: 37198420 PMC: 10485188. DOI: 10.1007/s42770-023-00998-0.


Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy.

Gong W, Wu X Front Microbiol. 2021; 12:745592.

PMID: 34745048 PMC: 8570039. DOI: 10.3389/fmicb.2021.745592.


YrbE3A Promotes Host Innate Immune Response by Targeting NF-κB/JNK Signaling.

Wang J, Zhu X, Peng Y, Zhu T, Liu H, Zhu Y Microorganisms. 2020; 8(4).

PMID: 32316659 PMC: 7232258. DOI: 10.3390/microorganisms8040584.


References
1.
Chen J, Wang S, Zhang Y, Su X, Wu J, Shao L . Rv1985c, a promising novel antigen for diagnosis of tuberculosis infection from BCG-vaccinated controls. BMC Infect Dis. 2010; 10:273. PMC: 2949761. DOI: 10.1186/1471-2334-10-273. View

2.
Sterling T . New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med. 2008; 29(5):532-41. DOI: 10.1055/s-0028-1085704. View

3.
Youden W . Index for rating diagnostic tests. Cancer. 1950; 3(1):32-5. DOI: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3. View

4.
Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy H . Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis. 1999; 179(3):637-45. DOI: 10.1086/314640. View

5.
Brock I, Weldingh K, Leyten E, Arend S, Ravn P, Andersen P . Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol. 2004; 42(6):2379-87. PMC: 427833. DOI: 10.1128/JCM.42.6.2379-2387.2004. View